For adult patients with metastatic HER2+ who have BC had two or more prior anti-HER2-based regimens in the metastatic setting, the FDA authorised neratinib (in combination with capecitabine) on 25 February 2020 (Dai et al., 2021). The gene discussed is ERBB2; the disease is breast cancer.